Belhaven Biopharma Inc.

Based in North Carolina, US, and founded in 2021, Belhaven Biopharma Inc. operates as a biopharmaceutical company specializes in developing dry powder nasal medicines. In January 2025, Belhaven Biopharma Inc. raised USD 11 million in venture funding.

The firm as of February 2025, is led by its CEO and Chairman of the Board, Scott Lyman. The company specializes in solutions for emergency medication delivery, primarily through its flagship product, Nasdepi®, a dry powder nasal epinephrine formulation. This product is designed to provide rapid relief for individuals experiencing life-threatening allergic reactions, known as anaphylaxis, which affects over 4 million people globally each year. The intuitive nasal device features a fast-acting formula that is heat resistant and boasts a long shelf life, addressing critical challenges faced by patients and healthcare providers in emergency scenarios.

The primary end-users of Nasdepi® include individuals with severe allergies, caregivers, and healthcare professionals who require reliable and easily administered treatment options in urgent situations.   Belhaven Biopharma's revenue generation model is structured around direct-to-consumer sales, partnerships with healthcare providers, and potential agreements with pharmacies and wholesalers.  In August 2025, Belhaven Biopharma Inc. raised USD 10 million in series A funding from unspecified investors.

The company plans to utilize the August 2025 funding to complete clinical trials and scale manufacturing of a needle-free, heat-stable intranasal epinephrine product for emergency allergy treatment.